MCB
Metropolitan Bank Holding Corp.
MCB has the edge over MS overall, supported by stronger fundamentals and stronger valuation.
MS
Morgan Stanley
MS has lower modeled downside risk, despite its lower overall score.
MCB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MCB's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MCB.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
MCB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $72.70 | -25% |
| Forward | 9x | $97.11 | — |
| Current | 9.9x | $97.11 | — |
| Fair | 11x | $105 | +8.4% |
| Expensive | 13x | $132 | +35% |
Historical ranges are pointers, not guarantees.
MCB's PE is in its fair range at 9.9x. If earnings grow as analysts expect, today's price would be 9.0x next year's earnings.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS has the edge over MCB in the historical PE scenario, which offers more potential upside but is not a forecast.
MCB Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MCB, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
MCB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.76 | +10% |
| Q3 2026 | $9.78 | +69% |
| Q2 2026 | $7.87 | +27% |
| Q1 2026 | $8.09 | +37% |
| Q4 2025 | $6.62 | +12% |
| Q3 2025 | $5.77 | +7.6% |
| Q2 2025 | $6.18 | -1.1% |
| Q1 2025 | $5.92 | -3.3% |
| Q4 2024 | $5.93 | -14% |
MCB earned $9.78 per share over the past year, up 69% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over MCB on earnings, with more consistent year-over-year improvement.
MCB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $100.6M | +26% |
| Q2 2026 | $93M | +22% |
| Q1 2026 | $88.5M | +25% |
| Q4 2025 | $88.4M | +25% |
| Q3 2025 | $79.8M | +12% |
| Q2 2025 | $76.3M | +13% |
| Q1 2025 | $70.6M | +5.8% |
| Q4 2024 | $71M | +12% |
MCB has the edge over MS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 46% | +33 points |
| Q2 2026 | 30% | -5.1 points |
| Q1 2026 | 50% | +17 points |
| Q4 2025 | 47% | +2.4 points |
| Q3 2025 | 13% | -12 points |
| Q2 2025 | 35% | -0.2 points |
| Q1 2025 | 33% | -3.3 points |
| Q4 2024 | 44% | +13 points |
MCB has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
MCB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $61.5M | +93% |
| Q2 2026 | -$10.8M | -159% |
| Q1 2026 | $55M | +609% |
| Q4 2025 | $30.7M | -63% |
| Q3 2025 | $31.8M | +562% |
| Q2 2025 | $18.4M | -48% |
| Q1 2025 | $7.8M | -69% |
| Q4 2024 | $83.4M | +$114.2M |
MCB has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
MCB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +55K shares |
| 1 year | +19% | +2M shares |
| 3 years | +13% | +1.4M shares |
| 5 years | +41% | +3.7M shares |
| Available history | +51% | +4.2M shares |
MCB has 13M diluted shares, up 19% from a year ago, despite $40M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $9.8M |
| Q2 2026 | — |
| Q1 2026 | $9.9M |
| Q4 2025 | $20.2M |
| Q3 2025 | $2.7M |
| Q2 2025 | $37.6M |
| Q1 2025 | $12.9M |
MCB spent $40M buying back its own shares over the past year.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over MCB on shareholder dilution, with a more favorable share count trend.
MCB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.1x | Net Cash |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | 0.4x | Very low |
MCB has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
MCB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 78.7 | Neutral |
MCB's weekly RSI is 60 (neutral) and its Stochastic is 79 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
MCB PE vs Financial Services Sector
| Metric | MCB | Sector median | Relative |
|---|---|---|---|
| PE | 9.9x | 13x | 24% below |
| PE % | 44 | 63 | 19 pts below |
MCB has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
MCB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $92.2 | 5.3% above |
| 20 week MA | $93.0 | 4.5% above |
| 50 week MA | $89.2 | 8.9% above |
| 100 week MA | $77.8 | 25% above |
| 200 week MA | $60.9 | 60% above |
MCB has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
MCB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.9 | $35.8 | -25% |
| 2021 | $35.8 | $100.4 | +180% |
| 2022 | $100.4 | $57.9 | -42% |
| 2023 | $57.9 | $55.4 | -4.3% |
| 2024 | $55.4 | $58.2 | +5% |
| 2025 | $58.2 | $78.3 | +35% |
| 2026 YTD | $78.3 | $97.1 | +24% |
MCB has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.